A Prospecitve Multicenter, Observational Registry Study
ConditionChronic Kidney Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorAstraZeneca
About this trial
This is a prospective, multicenter, observational registry study designed to collect data to deepen the understanding of CKD therapeutics, changes in clinical practice, cardiorenal risk outcomes and differences in treatment approaches in Chinese CKD patients.
Eligibility criteria
Qualifiers
Male or female patients aged ≥18 years.
Willing and able to provide written informed consent to participate in the study.
eGFR <60 mL/min/1.73 m² for ≥3 months, OR
Evidence of kidney damage (e.g., UACR ≥30 mg/g or UPCR ≥150 mg/g, structural abnormality on imaging, or kidney biopsy findings consistent with chronic kidney injury) persisting for ≥3 months
Disqualifiers
Having a life-threatening comorbidity with life expectancy < 2 years.
Severe cardiac disease: life-threatening arrhythmias, or recent MACE (Myocardial infarction (MI), stroke, CV death) within the past 3 months.
Pregnant or breastfeeding women.
Currently enrolled in any interventional clinical trial or receiving investigational therapy within 3 months of enrollment.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Locations
1Zhongshan Hospital Affilicated with Fudan University Shanghai China
Sponsors and collaborators
AstraZeneca
Lead sponsor
Source ClinicalTrials.gov